188 related articles for article (PubMed ID: 37850581)
21. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
[TBL] [Abstract][Full Text] [Related]
22. Integration of gadolinium in nanostructure for contrast enhanced-magnetic resonance imaging.
Marasini R; Thanh Nguyen TD; Aryal S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jan; 12(1):e1580. PubMed ID: 31486295
[TBL] [Abstract][Full Text] [Related]
23. MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents: Gadolinium Retention and Nephrogenic Systemic Fibrosis.
McDonald JS; McDonald RJ
Magn Reson Imaging Clin N Am; 2020 Nov; 28(4):497-507. PubMed ID: 33040991
[TBL] [Abstract][Full Text] [Related]
24. Gadolinium-based contrast agents in children.
Rozenfeld MN; Podberesky DJ
Pediatr Radiol; 2018 Aug; 48(9):1188-1196. PubMed ID: 30078039
[TBL] [Abstract][Full Text] [Related]
25. Gadolinium-based contrast agents: A comprehensive risk assessment.
Fraum TJ; Ludwig DR; Bashir MR; Fowler KJ
J Magn Reson Imaging; 2017 Aug; 46(2):338-353. PubMed ID: 28083913
[TBL] [Abstract][Full Text] [Related]
26. Gadolinium-containing MRI contrast agents: important variations on a theme for NSF.
Kuo PH
J Am Coll Radiol; 2008 Jan; 5(1):29-35. PubMed ID: 18180006
[TBL] [Abstract][Full Text] [Related]
27. Safety issues related to intravenous contrast agent use in magnetic resonance imaging.
Ponrartana S; Moore MM; Chan SS; Victoria T; Dillman JR; Chavhan GB
Pediatr Radiol; 2021 May; 51(5):736-747. PubMed ID: 33871726
[TBL] [Abstract][Full Text] [Related]
28. Practical recommendations for the safe use of gadolinium in magnetic resonance imaging: a Delphi expert panel study.
Baroni RH; Bauab T; Bittencourt LK; D'Ippolito G; Goldman SM; Hohgraefe Neto G; Manzella A; Rocha AJ; Sonoda LA; Takeda FS
Radiol Bras; 2020; 53(4):216-222. PubMed ID: 32904664
[TBL] [Abstract][Full Text] [Related]
29. Gadolinium retention: should pediatric radiologists be concerned, and how to frame conversations with families.
Noda SM; Oztek MA; Stanescu AL; Maloney E; Shaw DWW; Iyer RS
Pediatr Radiol; 2022 Feb; 52(2):345-353. PubMed ID: 33978802
[TBL] [Abstract][Full Text] [Related]
30. [Kidney and iodinated and gadolinium-based contrast agents].
Clément O; Faye N; Fournier L; Siauve N; Frija G
J Radiol; 2011 Apr; 92(4):291-8. PubMed ID: 21549885
[TBL] [Abstract][Full Text] [Related]
31. Use and Safety of Gadolinium Based Contrast Agents in Pediatric MR Imaging.
Holowka S; Shroff M; Chavhan GB
Indian J Pediatr; 2019 Oct; 86(10):961-966. PubMed ID: 30796704
[TBL] [Abstract][Full Text] [Related]
32. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
Prince MR; Zhang HL; Prowda JC; Grossman ME; Silvers DN
Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
[TBL] [Abstract][Full Text] [Related]
33. Gadolinium-Based Contrast Agent Use, Their Safety, and Practice Evolution.
Do C; DeAguero J; Brearley A; Trejo X; Howard T; Escobar GP; Wagner B
Kidney360; 2020 Jun; 1(6):561-568. PubMed ID: 34423308
[TBL] [Abstract][Full Text] [Related]
34. Nephrogenic systemic fibrosis: A survey of the use of gadolinium-based contrast agents in Ghana.
Piersson AD; Gorleku PN
Radiography (Lond); 2017 Nov; 23(4):e108-e113. PubMed ID: 28965904
[TBL] [Abstract][Full Text] [Related]
35. Gadolinium Deposition in Neurology Clinical Practice.
Smith TE; Steven A; Bagert BA
Ochsner J; 2019; 19(1):17-25. PubMed ID: 30983897
[No Abstract] [Full Text] [Related]
36. Gadolinium-based contrast agents - what is the evidence for 'gadolinium deposition disease' and the use of chelation therapy?
Layne KA; Wood DM; Dargan PI
Clin Toxicol (Phila); 2020 Mar; 58(3):151-160. PubMed ID: 31663374
[No Abstract] [Full Text] [Related]
37. 10 Years of Nephrogenic Systemic Fibrosis: A Comprehensive Analysis of Nephrogenic Systemic Fibrosis Reports Received by a Pharmaceutical Company from 2006 to 2016.
Endrikat J; Dohanish S; Schleyer N; Schwenke S; Agarwal S; Balzer T
Invest Radiol; 2018 Sep; 53(9):541-550. PubMed ID: 29547493
[TBL] [Abstract][Full Text] [Related]
38. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis.
Attari H; Cao Y; Elmholdt TR; Zhao Y; Prince MR
Radiology; 2019 Aug; 292(2):376-386. PubMed ID: 31264946
[TBL] [Abstract][Full Text] [Related]
39. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study.
Amet S; Launay-Vacher V; Clément O; Frances C; Tricotel A; Stengel B; Gauvrit JY; Grenier N; Reinhardt G; Janus N; Choukroun G; Laville M; Deray G
Invest Radiol; 2014 Feb; 49(2):109-15. PubMed ID: 24169070
[TBL] [Abstract][Full Text] [Related]
40. Gadolinium contrast agents - are they really safe?
Malikova H; Holesta M
J Vasc Access; 2017 Mar; 18(Suppl. 2):1-7. PubMed ID: 28362042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
